{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T09:38:39Z","timestamp":1776591519302,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The outcomes of percutaneous coronary intervention (PCI) in diabetic patients are still suboptimal, and it is unclear if diabetic patients might derive a benefit from the use of drug-coated balloons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To evaluate the impact of diabetes mellitus on the outcomes of patients undergoing PCI with sirolimus-coated balloon (SCB) MagicTouch (Concept Medical, India).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a subgroup analysis of the prospective, multicenter, investigator-initiated EASTBOURNE registry, evaluating the performance of MagicTouch SCB in patients with and without diabetes. The study primary endpoint was target lesion revascularization (TLR) at 12-month follow-up. Secondary clinical endpoints were major adverse clinical events (MACE), death, myocardial infarction (MI), and BARC 2\u20135 bleedings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 2,083 enrolled patients, a total of 864 suffered from diabetes (41.5%). Patients with diabetes had a numerically higher occurrence of TLR (6.5% vs. 4.7% HR 1.38, 95%CI 0.91\u20132.08), all-cause death (3.8% vs. 2.6%, HR 1.81, 95%CI 0.95\u20133.46), and MACE (12.2% vs. 8.9%; HR 1.26 95%CI 0.92\u20131.74). The incidence of spontaneous MI was significantly higher among diabetic patients (3.4% vs. 1.5%, HR 2.15 95%CI 1.09\u20134.25); bleeding events did not significantly differ. The overall incidence of TLR was higher among in-stent restenosis (ISR) as compared to de-novo coronary lesions, irrespectively from diabetes status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the EASTBOURNE DIABETES registry, diabetic patients treated with the MagicTouch SCB did not have a significant increase in TLR when compared to non-diabetic patients; moreover, diabetic status did not affect the study device performance in terms of TLR, in both de-novo lesions and ISR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02139-9","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T13:02:32Z","timestamp":1706965352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry"],"prefix":"10.1186","volume":"23","author":[{"given":"Gianluca","family":"Caiazzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tay M.","family":"Heang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuey Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Milazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pesenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mangieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the EASTBOURNE investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"issue":"3","key":"2139_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0735-1097(02)01971-X","volume":"40","author":"E Van Belle","year":"2002","unstructured":"Van Belle E, P\u00e9ri\u00e9 M, Braune D, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol. 2002;40(3):410\u20137. https:\/\/doi.org\/10.1016\/S0735-1097(02)01971-X.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2139_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/01.CIR.0000109693.64957.20","volume":"109","author":"V Mathew","year":"2004","unstructured":"Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its outcomes (PRESTO) trial. Circulation. 2004;109(4):476\u201380. https:\/\/doi.org\/10.1161\/01.CIR.0000109693.64957.20.","journal-title":"Circulation"},{"key":"2139_CR3","doi-asserted-by":"publisher","unstructured":"ME F., M D., LA S., et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012;367(25). https:\/\/doi.org\/10.1056\/NEJMOA1211585.","DOI":"10.1056\/NEJMOA1211585"},{"issue":"24","key":"2139_CR4","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/J.JCIN.2018.09.033","volume":"11","author":"M Konigstein","year":"2018","unstructured":"Konigstein M, Ben-Yehuda O, Smits PC, et al. Outcomes among Diabetic patients undergoing percutaneous coronary intervention with Contemporary Drug-Eluting stents: analysis from the BIONICS Randomized Trial. JACC Cardiovasc Interv. 2018;11(24):2467\u201376. https:\/\/doi.org\/10.1016\/J.JCIN.2018.09.033.","journal-title":"JACC Cardiovasc Interv"},{"key":"2139_CR5","doi-asserted-by":"publisher","unstructured":"Lenz T, Koch T, Joner M, et al. Ten-year clinical outcomes of Biodegradable Versus durable polymer New-Generation drug-eluting stent in patients with coronary artery Disease With and without diabetes Mellitus. J Am Heart Assoc. 2021;10(12). https:\/\/doi.org\/10.1161\/JAHA.120.020165.","DOI":"10.1161\/JAHA.120.020165"},{"issue":"16","key":"2139_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/J.JCIN.2021.06.025","volume":"14","author":"J W\u00f6hrle","year":"2021","unstructured":"W\u00f6hrle J, Scheller B, Seeger J, et al. Impact of diabetes on Outcome with Drug-Coated balloons Versus Drug-Eluting stents: the BASKET-SMALL 2 Trial. JACC Cardiovasc Interv. 2021;14(16):1789\u201398. https:\/\/doi.org\/10.1016\/J.JCIN.2021.06.025.","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"2139_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/J.JCIN.2020.02.043","volume":"13","author":"RV Jeger","year":"2020","unstructured":"Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv. 2020;13(12):1391\u2013402. https:\/\/doi.org\/10.1016\/J.JCIN.2020.02.043.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10261","key":"2139_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0140-6736(20)32173-5","volume":"396","author":"RV Jeger","year":"2020","unstructured":"Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396(10261):1504\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(20)32173-5.","journal-title":"Lancet"},{"issue":"8","key":"2139_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/J.JCIN.2015.04.008","volume":"8","author":"A Latib","year":"2015","unstructured":"Latib A, Ruparelia N, Menozzi A, et al. 3-Year Follow-Up of the balloon elution and late loss optimization study (BELLO). JACC Cardiovasc Interv. 2015;8(8):1132\u20134. https:\/\/doi.org\/10.1016\/J.JCIN.2015.04.008.","journal-title":"JACC Cardiovasc Interv"},{"issue":"9865","key":"2139_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(12)61964-3","volume":"381","author":"RA Byrne","year":"2013","unstructured":"Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(12)61964-3.","journal-title":"Lancet"},{"issue":"5","key":"2139_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/HEARTJNL-2012-302945","volume":"99","author":"A Indermuehle","year":"2013","unstructured":"Indermuehle A, Bahl R, Lansky AJ, et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99(5):327\u201333. https:\/\/doi.org\/10.1136\/HEARTJNL-2012-302945.","journal-title":"Heart"},{"issue":"4","key":"2139_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.23736\/S0026-4725.18.04641-8","volume":"66","author":"B Cortese","year":"2018","unstructured":"Cortese B, Palma DI, Latini G. Magic Touch\u00ae: preliminary clinical evidence with a novel sirolimus drug coated balloon. Minerva Cardioangiol. 2018;66(4):508\u201317. https:\/\/doi.org\/10.23736\/S0026-4725.18.04641-8.","journal-title":"Minerva Cardioangiol"},{"issue":"2","key":"2139_CR13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2459\/JCM.0000000000001070","volume":"22","author":"B Cortese","year":"2021","unstructured":"Cortese B, Testa L, Di Palma G, et al. Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry. J Cardiovasc Med (Hagerstown). 2021;22(2):94\u2013100. https:\/\/doi.org\/10.2459\/JCM.0000000000001070.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"15","key":"2139_CR14","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1056\/NEJME1616575","volume":"376","author":"JR Ingelfinger","year":"2017","unstructured":"Ingelfinger JR, Jarcho JA. Increase in the incidence of diabetes and its implications. N Engl J Med. 2017;376(15):1473\u20134. https:\/\/doi.org\/10.1056\/NEJME1616575.","journal-title":"N Engl J Med"},{"issue":"12","key":"2139_CR15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/J.AMJCARD.2018.02.034","volume":"121","author":"SH Pi","year":"2018","unstructured":"Pi SH, Rhee TM, Lee JM, et al. Outcomes in patients with diabetes Mellitus according to insulin treatment after percutaneous coronary intervention in the second-generation drug-eluting stent era. Am J Cardiol. 2018;121(12):1505\u201311. https:\/\/doi.org\/10.1016\/J.AMJCARD.2018.02.034.","journal-title":"Am J Cardiol"},{"key":"2139_CR16","doi-asserted-by":"publisher","unstructured":"Tachkov K, Mitov K, Koleva Y, et al. Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. PLoS ONE. 2020;15(5). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0232815.","DOI":"10.1371\/JOURNAL.PONE.0232815"},{"key":"2139_CR17","doi-asserted-by":"publisher","unstructured":"Wilson S, Mone P, Kansakar U, et al. Diabetes and restenosis. Cardiovasc Diabetol. 2022;21(1). https:\/\/doi.org\/10.1186\/S12933-022-01460-5.","DOI":"10.1186\/S12933-022-01460-5"},{"key":"2139_CR18","doi-asserted-by":"publisher","unstructured":"Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(1). https:\/\/doi.org\/10.1186\/S10020-018-0060-3.","DOI":"10.1186\/S10020-018-0060-3"},{"key":"2139_CR19","doi-asserted-by":"publisher","unstructured":"Zhao L, Zhu W, Zhang X, He D, Guo C. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord. 2017;17(1). https:\/\/doi.org\/10.1186\/S12872-016-0445-6.","DOI":"10.1186\/S12872-016-0445-6"},{"issue":"8","key":"2139_CR20","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jacc.2003.04.004","volume":"43","author":"R Mehran","year":"2004","unstructured":"Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol. 2004;43(8):1348\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2003.04.004.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2139_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCINTERVENTIONS.110.959924","volume":"4","author":"C Briguori","year":"2011","unstructured":"Briguori C, Airoldi F, Visconti G, et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv. 2011;4(2):121\u20139. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.110.959924.","journal-title":"Circ Cardiovasc Interv"},{"issue":"42","key":"2139_CR22","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1093\/EURHEARTJ\/EHX512","volume":"38","author":"J Escaned","year":"2017","unstructured":"Escaned J, Collet C, Ryan N, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. Eur Heart J. 2017;38(42):3124\u201334. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHX512.","journal-title":"Eur Heart J"},{"issue":"4","key":"2139_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/J.AMJCARD.2005.09.084","volume":"97","author":"CW Lee","year":"2006","unstructured":"Lee CW, Park DW, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol. 2006;97(4):506\u201311. https:\/\/doi.org\/10.1016\/J.AMJCARD.2005.09.084.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2139_CR24","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/S00392-021-01854-7","volume":"110","author":"T Koch","year":"2021","unstructured":"Koch T, Lenz T, Joner M, et al. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus: results of the Intracoronary Stenting and Angiographic results: test efficacy of Sirolimus- and probucol- and zotarolimus-eluting stents (ISAR-TEST 5) trial. Clin Res Cardiol. 2021;110(10):1586\u201398. https:\/\/doi.org\/10.1007\/S00392-021-01854-7.","journal-title":"Clin Res Cardiol"},{"key":"2139_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/J.ATHEROSCLEROSIS.2020.01.002","volume":"295","author":"P Chichareon","year":"2020","unstructured":"Chichareon P, Modolo R, Kogame N, et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis. 2020;295:45\u201353. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2020.01.002.","journal-title":"Atherosclerosis"},{"issue":"6","key":"2139_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1097\/SLA.0000000000005391","volume":"275","author":"R El-Andari","year":"2022","unstructured":"El-Andari R, Bozso SJ, Fialka NM, Kang JJH, Nagendran J, Nagendran J. Coronary revascularization for patients with diabetes Mellitus: a contemporary systematic review and Meta-analysis. Ann Surg. 2022;275(6):1058\u201366. https:\/\/doi.org\/10.1097\/SLA.0000000000005391.","journal-title":"Ann Surg"},{"issue":"3","key":"2139_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/S00392-014-0775-2","volume":"104","author":"FX Kleber","year":"2015","unstructured":"Kleber FX, Schulz A, Waliszewski M, et al. Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. Clin Res Cardiol. 2015;104(3):217\u201325. https:\/\/doi.org\/10.1007\/S00392-014-0775-2.","journal-title":"Clin Res Cardiol"},{"issue":"18","key":"2139_CR28","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/J.JACC.2012.07.040","volume":"60","author":"J W\u00f6hrle","year":"2012","unstructured":"W\u00f6hrle J, Zadura M, M\u00f6bius-Winkler S, et al. SeQuentPlease World wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J Am Coll Cardiol. 2012;60(18):1733\u20138. https:\/\/doi.org\/10.1016\/J.JACC.2012.07.040.","journal-title":"J Am Coll Cardiol"},{"key":"2139_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.CARREV.2021.04.013","volume":"28","author":"B Cortese","year":"2021","unstructured":"Cortese B, Caiazzo G, Di Palma G, De Rosa S. Comparison between Sirolimus- and paclitaxel-coated balloon for revascularization of coronary arteries: the SIRPAC (SIRolimus-PAClitaxel) Study. Cardiovasc Revasc Med. 2021;28:1\u20136. https:\/\/doi.org\/10.1016\/J.CARREV.2021.04.013.","journal-title":"Cardiovasc Revasc Med"},{"issue":"7","key":"2139_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/J.CARREV.2017.03.025","volume":"18","author":"B Cortese","year":"2017","unstructured":"Cortese B, di Palma G, Latini RA, Elwany M, Orrego PS, Seregni RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med. 2017;18(7):487\u201391. https:\/\/doi.org\/10.1016\/J.CARREV.2017.03.025.","journal-title":"Cardiovasc Revasc Med"},{"issue":"7","key":"2139_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2459\/JCM.0000000000000806","volume":"20","author":"B Cortese","year":"2019","unstructured":"Cortese B, Pellegrini D, Latini RA, Palma G, Di., Perotto A, Orrego PS. Angiographic performance of a novel sirolimus-coated balloon in native coronary lesions: the FAtebenefratelli SIrolimus COated NATIVES prospective registry. J Cardiovasc Med (Hagerstown). 2019;20(7):471\u20136. https:\/\/doi.org\/10.2459\/JCM.0000000000000806.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"3","key":"2139_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/J.CARREV.2018.06.003","volume":"20","author":"S Dani","year":"2019","unstructured":"Dani S, Shah D, Sojitra P, et al. A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanolut\u00e9 Registry. Cardiovasc Revasc Med. 2019;20(3):235\u201340. https:\/\/doi.org\/10.1016\/J.CARREV.2018.06.003.","journal-title":"Cardiovasc Revasc Med"},{"key":"2139_CR33","doi-asserted-by":"publisher","unstructured":"Caiazzo G, De Michele M, Golino L, Manganiello V, Fattore L. Sirolimus-Eluting balloon for the treatment of coronary lesions in Complex ACS patients: the SELFIE Registry. J Interv Cardiol. 2020;2020. https:\/\/doi.org\/10.1155\/2020\/8865223.","DOI":"10.1155\/2020\/8865223"},{"key":"2139_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.CARREV.2020.10.004","volume":"25","author":"M Ono","year":"2021","unstructured":"Ono M, Kawashima H, Hara H, et al. A prospective Multicenter Randomized Trial to assess the effectiveness of the MagicTouch Sirolimus-Coated balloon in small vessels: Rationale and Design of the TRANSFORM I Trial. Cardiovasc Revasc Med. 2021;25:29\u201335. https:\/\/doi.org\/10.1016\/J.CARREV.2020.10.004.","journal-title":"Cardiovasc Revasc Med"},{"issue":"4","key":"2139_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/CCD.30358","volume":"100","author":"A Greco","year":"2022","unstructured":"Greco A, Sciahbasi A, Abizaid A, et al. Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: Rationale and design of the TRANSFORM II randomized clinical trial. Catheter Cardiovasc Interv. 2022;100(4):544\u201352. https:\/\/doi.org\/10.1002\/CCD.30358.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"2139_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/J.CARREV.2019.03.001","volume":"21","author":"M Megaly","year":"2020","unstructured":"Megaly M, Ali A, Abraham B, et al. Outcomes with drug-coated balloons in percutaneous coronary intervention in Diabetic patients. Cardiovasc Revasc Med. 2020;21(1):78\u201385. https:\/\/doi.org\/10.1016\/J.CARREV.2019.03.001.","journal-title":"Cardiovasc Revasc Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02139-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02139-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T13:03:54Z","timestamp":1706965434000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02139-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2139"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02139-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by local Ethics Committee and all patients provided written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}